CSL stock price ends higher after Eli Lilly clazakizumab deal, with buyback in the background
CSL Ltd shares rose as much as 2.1% Wednesday after announcing a $100 million licensing deal with Eli Lilly for the kidney drug clazakizumab. CSL closed up 0.78% at A$152.74. The company also bought back 50,829 shares Tuesday, bringing total repurchases to over 3.2 million. The ASX200 index edged up 0.16%.